$276.8 K

SYN Mkt cap, 16-Aug-2018
Synthetic Biologics Net income (FY, 2018)-13.4 M
Synthetic Biologics EBIT (FY, 2018)-17.6 M
Synthetic Biologics Cash, 31-Dec-201828.9 M

Synthetic Biologics Income Statement

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

R&D expense

6.5m14.5m32.9m29.1m18.8m11.8m

General and administrative expense

5.8m6.0m8.1m10.1m7.5m5.7m

Operating expense total

12.3m20.5m41.0m39.3m26.3m17.6m

EBIT

(12.3m)(20.5m)(41.0m)(39.3m)(26.3m)(17.6m)

Interest income

33.0k3.0k6.0k37.0k21.0k67.0k

Net Income

(12.3m)(19.8m)(44.8m)(27.8m)(15.5m)(13.4m)

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q3, 2017Q1, 2018Q2, 2018

R&D expense

1.5m2.7m2.8m3.7m6.5m7.5m10.0m8.2m7.2m7.1m6.1m4.1m3.4m3.6m

General and administrative expense

1.9m1.1m1.8m1.2m1.7m2.2m1.6m2.4m2.1m2.1m2.1m1.7m1.6m1.4m

Operating expense total

3.4m3.8m4.7m4.9m8.2m9.7m11.7m10.6m9.3m9.2m8.1m5.8m5.0m5.0m

EBIT

(3.4m)(3.8m)(4.7m)(4.9m)(8.2m)(9.7m)(11.6m)(10.6m)(9.3m)(9.2m)(8.1m)(5.8m)(5.0m)(5.0m)

Interest income

11.0k1.0k1.0k1.0k2.0k2.0k1.0k34.0k1.0k1.0k4.0k9.0k6.0k

Net Income

(3.4m)(3.8m)(4.6m)(4.9m)(12.4m)(13.6m)(7.5m)(11.1m)(5.8m)(8.5m)(3.1m)(10.9m)(2.3m)(4.2m)

Synthetic Biologics Balance Sheet

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

14.6m17.5m20.8m19.1m17.1m28.9m

Inventories

1.6m1.5m9.5m2.5m

Current Assets

16.2m19.1m30.3m21.6m17.9m29.5m

PP&E

37.0k65.0k494.0k905.0k872.0k607.0k

Total Assets

16.3m19.1m30.8m22.5m18.8m30.1m

Accounts Payable

142.0k996.0k4.4m2.0m2.0m1.0m

Current Liabilities

1.0m9.6m15.6m19.8m9.8m3.4m

Total Liabilities

1.0m15.8m20.2m10.2m3.7m

Additional Paid-in Capital

96.4m110.5m160.7m175.8m192.5m230.8m

Retained Earnings

(81.3m)(101.0m)(144.8m)(172.0m)(194.2m)(219.5m)

Total Equity

15.2m15.0m2.2m(3.4m)14.2m

Financial Leverage

1.1 x2.1 x10 x-5.5 x2.1 x

Synthetic Biologics Cash Flow

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(12.3m)(19.8m)(44.8m)(27.8m)(15.5m)(13.4m)

Depreciation and Amortization

43.0k20.0k72.0k157.0k245.0k272.0k

Inventories

855.0k43.0k(8.0m)7.0m

Accounts Payable

(253.0k)854.0k3.4m(2.4m)27.0k(987.0k)

Cash From Operating Activities

(7.7m)(16.1m)(38.9m)(27.9m)(17.3m)

Purchases of PP&E

(36.0k)(48.0k)(501.0k)(569.0k)(212.0k)(7.0k)

Cash From Investing Activities

(36.0k)(48.0k)(501.0k)(569.0k)(7.0k)

Cash From Financing Activities

12.4m19.0m42.7m26.7m18.5m29.1m

Interest Paid

Income Taxes Paid

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q3, 2017Q1, 2018Q2, 2018

Net Income

(8.1m)(3.8m)(8.4m)(13.3m)(12.4m)(26.0m)(33.5m)(11.1m)(16.8m)(8.5m)(3.1m)(18.3m)(2.3m)(6.5m)

Depreciation and Amortization

33.0k3.0k7.0k13.0k8.0k19.0k39.0k37.0k57.0k57.0k172.0k71.0k141.0k

Accounts Payable

189.0k631.0k937.0k731.0k563.0k7.7m5.0m184.0k143.0k4.2m1.8m(895.0k)(527.0k)(803.0k)

Cash From Operating Activities

(5.0m)(3.5m)(6.8m)(11.3m)(5.5m)(12.7m)(27.9m)(5.7m)(11.5m)(6.0m)(16.3m)(6.1m)(10.4m)

Purchases of PP&E

(25.0k)(4.0k)(21.0k)(43.0k)(18.0k)(61.0k)(457.0k)(44.0k)(45.0k)(11.0k)(209.0k)

Cash From Investing Activities

(25.0k)(4.0k)(21.0k)(43.0k)(18.0k)(61.0k)(457.0k)(44.0k)(45.0k)(11.0k)(209.0k)

Cash From Financing Activities

231.0k4.0k4.0k4.0k1.0k42.7m810.0k435.0k18.5m400.0k

Interest Paid

Income Taxes Paid

Synthetic Biologics Ratios

USDY, 2018

Financial Leverage

2.1 x